87 related articles for article (PubMed ID: 2187326)
1. Effects of fluoride treatment on bone strength.
Carter DR; Beaupré GS
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S177-84. PubMed ID: 2187326
[TBL] [Abstract][Full Text] [Related]
2. The effects of fluoridated water on bone strength.
Turner CH; Akhter MP; Heaney RP
J Orthop Res; 1992 Jul; 10(4):581-7. PubMed ID: 1613632
[TBL] [Abstract][Full Text] [Related]
3. Fluoride effects on bone crystals.
Grynpas MD
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S169-75. PubMed ID: 2187325
[TBL] [Abstract][Full Text] [Related]
4. [Loss of trabecular bone strength and bone quality after 5 years of fluoride therapy for osteoporosis].
Søgaard CH; Mosekilde L; Richards A; Mosekilde L
Ugeskr Laeger; 1995 Apr; 157(14):2004-8. PubMed ID: 7740640
[TBL] [Abstract][Full Text] [Related]
5. Effect of controlled local release of sodium fluoride on trabecular bone.
Guise JM; McCormack A; Anderson PA; Tencer AF
J Orthop Res; 1992 Jul; 10(4):588-95. PubMed ID: 1613633
[TBL] [Abstract][Full Text] [Related]
6. [Effects of bisphosphonates on the mechanical efficiency of normal and osteopenic bones].
Ferretti JL; Cointry GR; Capozza RF; Mondelo N; Peluffo V; Chiappe A; Meta M; Alippi RM
Medicina (B Aires); 1997; 57 Suppl 1():83-92. PubMed ID: 9567360
[TBL] [Abstract][Full Text] [Related]
7. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
8. Uniform partial dissolution of bone mineral by using fluoride and phosphate ions combination.
DePaula CA; Pan Y; Guzelsu N
Connect Tissue Res; 2008; 49(5):328-42. PubMed ID: 18991086
[TBL] [Abstract][Full Text] [Related]
9. Fluor in the treatment of osteoporosis. An overview of thirty years clinical research.
Dequeker J; Declerck K
Schweiz Med Wochenschr; 1993 Nov; 123(47):2228-34. PubMed ID: 8272793
[TBL] [Abstract][Full Text] [Related]
10. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys.
Fox J; Miller MA; Newman MK; Recker RR; Turner CH; Smith SY
Bone; 2007 Sep; 41(3):321-30. PubMed ID: 17573250
[TBL] [Abstract][Full Text] [Related]
11. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
12. Varying the mechanical properties of bone tissue by changing the amount of its structurally effective bone mineral content.
Kotha SP; Walsh WR; Pan Y; Guzelsu N
Biomed Mater Eng; 1998; 8(5-6):321-34. PubMed ID: 10081595
[TBL] [Abstract][Full Text] [Related]
13. Influence of bone volume fraction and architecture on computed large-deformation failure mechanisms in human trabecular bone.
Bevill G; Eswaran SK; Gupta A; Papadopoulos P; Keaveny TM
Bone; 2006 Dec; 39(6):1218-25. PubMed ID: 16904959
[TBL] [Abstract][Full Text] [Related]
14. Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice.
Fonseca D; Ward WE
Bone; 2004 Aug; 35(2):489-97. PubMed ID: 15268901
[TBL] [Abstract][Full Text] [Related]
15. Effect of ultrastructural changes on the toughness of bone.
Nyman JS; Reyes M; Wang X
Micron; 2005; 36(7-8):566-82. PubMed ID: 16169742
[TBL] [Abstract][Full Text] [Related]
16. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
Mori H; Tanaka M; Kayasuga R; Masuda T; Ochi Y; Yamada H; Kishikawa K; Ito M; Nakamura T
Bone; 2008 Nov; 43(5):840-8. PubMed ID: 18718565
[TBL] [Abstract][Full Text] [Related]
17. Severe bone alterations under beta2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats.
Bonnet N; Benhamou CL; Brunet-Imbault B; Arlettaz A; Horcajada MN; Richard O; Vico L; Collomp K; Courteix D
Bone; 2005 Nov; 37(5):622-33. PubMed ID: 16157516
[TBL] [Abstract][Full Text] [Related]
18. Increased calcium content and inhomogeneity of mineralization render bone toughness in osteoporosis: mineralization, morphology and biomechanics of human single trabeculae.
Busse B; Hahn M; Soltau M; Zustin J; Püschel K; Duda GN; Amling M
Bone; 2009 Dec; 45(6):1034-43. PubMed ID: 19679206
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
Day JS; Ding M; Bednarz P; van der Linden JC; Mashiba T; Hirano T; Johnston CC; Burr DB; Hvid I; Sumner DR; Weinans H
J Orthop Res; 2004 May; 22(3):465-71. PubMed ID: 15099622
[TBL] [Abstract][Full Text] [Related]
20. Bone morphometry and differences in bone fluorine containing compounds in rats treated with NaF and MFP.
Brun LR; Pera LI; Rigalli A
Biomed Pharmacother; 2010 Jan; 64(1):1-6. PubMed ID: 19800195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
